Kymera Therapeutics

General Information
Business:

 

We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus, allows us to discover highly selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities.

To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 55
Founded: 2015
Contact Information
Address 200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472, US
Phone Number (857) 285-5300
Web Address http://www.kymeratx.com
View Prospectus: Kymera Therapeutics
Financial Information
Market Cap $862.8mil
Revenues $9.5 mil (last 12 months)
Net Income $-56.9 mil (last 12 months)
IPO Profile
Symbol KYMR
Exchange NASDAQ
Shares (millions): 8.7
Price range $20.00 - $20.00
Est. $ Volume $173.7 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Cowen/ Guggenheim Securities
CO-Managers -
Expected To Trade: 8/21/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change